Ostrowski KA, Gannon JR, Walsh TJ. A review of the epidemiology and treatment of Peyronie’s disease. Res Rep Urol. 2016;8:61–70.

CAS  PubMed  PubMed Central  Google Scholar 

Stuntz M, Perlaky A, des Vignes F, Kyriakides T, Glass D. The prevalence of Peyronie’s disease in the United States: A Population-Based Study. PLoS ONE. 2016;11:e0150157.

PubMed  PubMed Central  Google Scholar 

Pryor J, Akkus E, Alter G, Jordan G, Lebret T, Levine L, et al. Peyronie’s disease. J Sex Med. 2004;1:110–5.

PubMed  Google Scholar 

Mulhall JP, Creech SD, Boorjian SA, Ghaly S, Kim ED, Moty A, et al. Subjective and objective analysis of the prevalence of Peyronie’s disease in a population of men presenting for prostate cancer screening. J Urol. 2004;171:2350–3.

PubMed  Google Scholar 

Nehra A, Alterowitz R, Culkin DJ, Faraday MM, Hakim LS, Heidelbaugh JJ, et al. Peyronie’s disease: AUA guideline. J Urol. 2015;194:745–53.

PubMed  PubMed Central  Google Scholar 

U.S. Food and Drug Administration. Center for drug evaluation and research. XIAFLEX® (collagenase clostridium histolyticum) approval letter. 2013. https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2013/125338Orig1s0061ltr.pdf.

Gelbard M, Goldstein I, Hellstrom WJ, McMahon CG, Smith T, Tursi J, et al. Clinical efficacy, safety and tolerability of collagenase clostridium histolyticum for the treatment of peyronie disease in 2 large double-blind, randomized, placebo controlled phase 3 studies. J Urol. 2013;190:199–207.

CAS  PubMed  Google Scholar 

Hu MY, Sigalos JT, Walker DT, Li MK, Yoffe DA, Modiri N, et al. Intralesional collagenase clostridium histolyticum for acute phase Peyronie’s disease: a single-center, retrospective cohort study. Transl Androl Urol. 2022;11:1074–82.

PubMed  PubMed Central  Google Scholar 

Nguyen HMT, Yousif A, Chung A, Virasoro R, Tapscott A, Ziegelmann M, et al. Safety and efficacy of collagenase clostridium histolyticum in the treatment of acute phase Peyronie’s disease: a multi-institutional analysis. Urology. 2020;145:147–51.

PubMed  Google Scholar 

Trost L, Mulhall J, Hellstrom W. Creation of a novel classification system (PTNM) for Peyronie’s disease and penile curvature using evidence-based criteria. J Urol. 2024;212:470–82.

PubMed  Google Scholar 

Flores JM, Nascimento B, Punjani N, Salter CA, Bernie HL, Taniguchi H, et al. Predictors of curvature improvement in men with Peyronie’s disease treated with intralesional collagenase clostridium histolyticum. J Sex Med. 2022;19:1680–6.

CAS  PubMed  PubMed Central  Google Scholar 

Kim HY. Statistical notes for clinical researchers: chi-squared test and Fisher’s exact test. Restor Dent Endod. 2017;42:152–5.

PubMed  PubMed Central  Google Scholar 

El-Khatib FM, Towe M, Yafi FA. Management of Peyronie’s disease with collagenase clostridium histolyticum in the acute phase. World J Urol. 2020;38:299–304.

PubMed  Google Scholar 

Hellstrom WJ, Feldman R, Rosen RC, Smith T, Kaufman G, Tursi J. Bother and distress associated with Peyronie’s disease: validation of the Peyronie’s disease questionnaire. J Urol. 2013;190:627–34.

PubMed  Google Scholar